CEPH Message Board - Msg: 1417938

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hedge who wrote (338)	5/16/1997 10:40:00 AM
From: Bill Bishop	of 998

Cephalon drug rejected, and investors are shocked From DBC News 5/16/97 SAN FRANCISCO (DBC) -- Investing in biotech companies is not for the faint of heart. Counting on the successful development of one or two miracle drugs, many of these companies go public with no revenue or commercial products. After years of costly research, testing and more testing, all it takes is one vote by the government's Food & Drug Adminstration to leave a development-stage biotech company and its investors back where they started. Take the case of Cephalon. The 10-year-old company had been developing the drug myotrophin in collaboration with Chiron Corp.. It treats ALS, or Lou Gherig's disease, a deadly neurological affliction for which there is no known cure and few treatment options... dbc.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next